MX2008006005A - Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados. - Google Patents

Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados.

Info

Publication number
MX2008006005A
MX2008006005A MX2008006005A MX2008006005A MX2008006005A MX 2008006005 A MX2008006005 A MX 2008006005A MX 2008006005 A MX2008006005 A MX 2008006005A MX 2008006005 A MX2008006005 A MX 2008006005A MX 2008006005 A MX2008006005 A MX 2008006005A
Authority
MX
Mexico
Prior art keywords
immunostimulatory oligonucleotide
immunostimulatory
oligonucleotide
oligonucleotides
tcg
Prior art date
Application number
MX2008006005A
Other languages
English (en)
Spanish (es)
Inventor
Sudhir Agrawal
Dong Yu
Ekambar R Kandimalla
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Publication of MX2008006005A publication Critical patent/MX2008006005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2008006005A 2005-11-07 2005-11-07 Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados. MX2008006005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/042068 WO2007055704A2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Publications (1)

Publication Number Publication Date
MX2008006005A true MX2008006005A (es) 2008-10-01

Family

ID=38023711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008006005A MX2008006005A (es) 2005-11-07 2005-11-07 Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados.

Country Status (8)

Country Link
EP (3) EP1942945B1 (cg-RX-API-DMAC7.html)
JP (1) JP5184366B2 (cg-RX-API-DMAC7.html)
CN (1) CN101351228A (cg-RX-API-DMAC7.html)
AT (1) ATE529511T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005338035B2 (cg-RX-API-DMAC7.html)
CA (1) CA2628306C (cg-RX-API-DMAC7.html)
MX (1) MX2008006005A (cg-RX-API-DMAC7.html)
WO (1) WO2007055704A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
KR101343489B1 (ko) * 2007-07-09 2013-12-20 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역 조절성 rna(simra)화합물
CA2693266C (en) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (cg-RX-API-DMAC7.html) 1992-07-23 1995-04-01 Tri Clover Inc
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
DE60017259T2 (de) 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
WO2001055370A2 (en) 2000-01-26 2001-08-02 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP4726630B2 (ja) * 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
US7498425B2 (en) * 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers

Also Published As

Publication number Publication date
JP5184366B2 (ja) 2013-04-17
EP2402442B1 (en) 2013-07-31
CA2628306A1 (en) 2007-05-18
AU2005338035A1 (en) 2007-05-18
EP2371956A3 (en) 2012-01-04
EP2402442A3 (en) 2012-03-28
EP1942945A2 (en) 2008-07-16
CA2628306C (en) 2014-06-17
WO2007055704A2 (en) 2007-05-18
EP2371956A2 (en) 2011-10-05
ATE529511T1 (de) 2011-11-15
WO2007055704A3 (en) 2007-12-06
EP1942945A4 (en) 2009-01-21
AU2005338035B2 (en) 2012-06-07
EP2402442A2 (en) 2012-01-04
JP2009514527A (ja) 2009-04-09
EP1942945B1 (en) 2011-10-19
CN101351228A (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
US7470674B2 (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AU2010210016B2 (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
AU2002365141B2 (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US20100254974A1 (en) Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends
EP1393745A1 (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
US20110305684A1 (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP5184366B2 (ja) 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性
AU2005338050B2 (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2012051921A (ja) 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性
HK1121954A (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
HK1122043A (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Legal Events

Date Code Title Description
FG Grant or registration